Meta-analysis confirms positive outcomes in patients implanted with Medtronic CoreValve System

A late-breaking presentation about transcatheter aortic valve implantation (TAVI) at EuroPCR 2011 today confirmed positive outcomes in patients receiving the CoreValve® System from Medtronic, Inc. (NYSE: MDT) across seven international clinical registries. The meta-analysis, undertaken by several leading international interventional cardiologists and presented during a late-breaking trial Hot Line session, summarized European data from 2,156 patients treated with the CoreValve System for severe aortic stenosis.

“There has been some variability in reported early and late outcomes with TAVI systems from individual country registries, which we believe can be attributed to limited sample sizes and different experience levels among physicians.”

"Our weighted analysis of early and late clinical outcomes after CoreValve implantation demonstrates that this transcatheter self-expandable valve prostheses provides a safe treatment alternative to patients who are at high-risk or unable to undergo surgical aortic valve replacement," said Carlos E. Ruiz, M.D., Ph.D., director of the Structural and Congenital Heart Program at Lenox Hill Heart and Vascular Institute of New York. "There has been some variability in reported early and late outcomes with TAVI systems from individual country registries, which we believe can be attributed to limited sample sizes and different experience levels among physicians."

The results demonstrate positive patient outcomes based on procedural success rate (97.8 percent), vascular complication rate (2.9 percent), one-month stroke rate (1.9 percent), one-month survival rate (93.8 percent) and one-year all-cause mortality rate from five registries (17.1 percent).

The meta-analysis included findings from Australia, Belgium, France, Germany, New Zealand, Spain and the United Kingdom. Medtronic provided financial support for the meta-analysis. Limitations of the meta-analysis included use of non-standard definitions by independent registries and independent reporting of clinical outcomes.

The CoreValve System is designed to provide a minimally invasive, non-surgical treatment option for patients with symptomatic, severe aortic stenosis who are at high risk, or are ineligible, for open-heart surgery. Worldwide, approximately 300,000 people have been diagnosed with this condition, and approximately one-third of these patients are deemed at too high a risk for open-heart surgery. Since 2007, the Medtronic CoreValve System has been implanted in more than 40 countries outside the U.S. The Medtronic CoreValve System is currently limited to investigational use in the United States.

Source:

Medtronic, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Medtronic. (2019, June 19). Meta-analysis confirms positive outcomes in patients implanted with Medtronic CoreValve System. News-Medical. Retrieved on May 28, 2022 from https://www.news-medical.net/news/20110520/Meta-analysis-confirms-positive-outcomes-in-patients-implanted-with-Medtronic-CoreValve-System.aspx.

  • MLA

    Medtronic. "Meta-analysis confirms positive outcomes in patients implanted with Medtronic CoreValve System". News-Medical. 28 May 2022. <https://www.news-medical.net/news/20110520/Meta-analysis-confirms-positive-outcomes-in-patients-implanted-with-Medtronic-CoreValve-System.aspx>.

  • Chicago

    Medtronic. "Meta-analysis confirms positive outcomes in patients implanted with Medtronic CoreValve System". News-Medical. https://www.news-medical.net/news/20110520/Meta-analysis-confirms-positive-outcomes-in-patients-implanted-with-Medtronic-CoreValve-System.aspx. (accessed May 28, 2022).

  • Harvard

    Medtronic. 2019. Meta-analysis confirms positive outcomes in patients implanted with Medtronic CoreValve System. News-Medical, viewed 28 May 2022, https://www.news-medical.net/news/20110520/Meta-analysis-confirms-positive-outcomes-in-patients-implanted-with-Medtronic-CoreValve-System.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
SLATE clinical trial uses Medtronic Visualase MRI-guided laser ablation system to treat common form of epilepsy